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Background: The purpose of this study was to evaluate the feasibility of the magnetic resonance (MR) conditional
pacemaker (PM) system (Evia SR-T and DR-T with Safio S leads) under MR conditions.
Methods: Patients with standard PM indications and Evia PM were eligible for enrollment in this single center
prospective non-randomized pilot study. Patients underwent MR of the brain and lower lumbar spine at 1.5 Tesla.
Atrial (RA) und ventricular (RV) lead parameters (sensing, pacing threshold [PTH], pacing impedance) were assessed
immediately before (baseline follow-up [FU]) and immediately after MRI (1st FU), after 1 month (2nd FU) and
3 months (3rd FU). The effect of MR on serious adverse device effect (SADE) free-rate, on atrial and ventricular
sensing (AS/VS; mV) and atrial (RA) and ventricular (RV) pacing thresholds (PTH; V/0.4 ms) were investigated
between baseline and 2nd FU. Continuous variables are expressed as mean ± SD and were compared using paired
Student’s t-test. A p < 0.05 was considered significant.
Results: Thirty-one patients were enrolled. One patient had to be excluded because of an enrollment violation.
Therefore, data of 30 patients (female 12 [40%], age 73 ± 12 years, dual chamber PM 15 [50%]) were included in this
analysis. No MR related SADE occurred. Lead measurements were not statistically different between the baseline FU
and the 2nd FU (AS/VS at baseline 3.2 ± 2.1/15.0 ± 6.0, at 2nd FU 3.2 ± 2.1/14.9 ± 6.5; p = ns. RA-PTH/RV-PTH at baseline
0.68 ± 0.18/0.78 ± 0.22, at 2nd FU 0.71 ± 0.24/0.78 ± 0.22; p = ns). The presence of the permanent pacemakers led to
MR imaging artifacts on diffusion weighted sequences of the brain, but did not affect other sequences (e.g. FLAIR
and T2 weighted spin-echo images).
Conclusion: The use of the MR conditional Evia PM in a MR environment under predefined conditions is feasible.
No MR related SADEs nor clinically relevant changes in device functions occurred.
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Magnetic resonance imaging (MRI) has become an im-
portant tool for diagnosis and therapy control of many
diseases [1]. Patients with cardiac implantable electronic
devices such as permanent pacemakers and implantable
defibrillators are usually excluded from MRI examina-
tions since the majority of implantable devices have a
contraindication for MRI [2,3]. Some larger series with
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distribution, and reproduction in any mediumacceptable risk-benefit ratio by taking MRI and pace-
maker related precautions [4-7]. Potential (adverse)
effects of MR on pacemaker function include effects
from different sources [2,7]. The static magnetic field
may induce mechanical forces on ferromagnetic compo-
nents, unpredictable magnetic sensor activation, reed-
switch closure and changes in electrocardiograms. Po-
tential effects from modulated radio frequency (RF)
fields are heating of cardiac tissue adjacent to lead elec-
trodes potentially leading to pacing threshold increases,
possible induction of arrhythmias, pacemaker repro-
gramming or reset, RF interactions with the device
(over-and undersensing). Gradient magnetic fields maytral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Wollmann et al. Journal of Cardiovascular Magnetic Resonance 2012, 14:67 Page 2 of 11
http://www.jcmr-online.com/content/14/1/67induce arrhythmias, and voltages on leads causing over-
and under-sensing. Combined field effects are alterations
of device function because of electro-magnetic interfer-
ence, mechanical forces (vibration), electrical reset of
devices, and damage to pacemaker and/or leads.
As a result of patients’ needs (and their physicians’)
different manufacturers recently market released per-
manent implantable pacemaker systems which are
designed with respect to the above mentioned potential
adverse effects of MR on permanent pacemakers. The
first of these especially designed pacemaker systems has
been proven in a prospective, randomized study pub-
lished showing the safety of a MR conditional dual
chamber pacemaker system [8].
By mid of 2010 the MR conditional EVIA pace-
maker systems (Biotronik SE & Co KG, Berlin, Ger-
many) became available in Europe, offering the Evia
pacemaker family [Evia SR(−T) and DR(−T)] with the
first MR conditional single chamber pacemaker sys-
tem [Evia SR(−T)].
The purpose of our study was to evaluate feasibility of
the new MR conditional pacemaker system (Evia SR-T
and DR-T with Safio S53/S60 active screw-in leads,
Biotronik SE &Co KG, Berlin, Germany) under specific
MR conditions. We report the results of the monocenter
feasibility study of the MRI compatibility of the Evia
pacemaker in combination with the Safio S pacemaker
lead.
Methods
From all patients implanted with permanent pacemakers
at the general hospital of St. Pölten-Lilienfeld those
patients implanted with Evia SR-T or DR-T PM and
Safio S leads at least 6 weeks before intended MR scan
were eligible for enrollment in this single center pro-
spective non-randomized pilot study. Pacemaker implan-
tations were indicated according to current guidelines
[9,10]. At enrollment pacing thresholds had to be ≤ 2.0
Volts/0.4 ms, pacing impedances between 200 and 1.500
Ohms. The charge state of the battery had to be at least
30%. Patients had to be afebrile. Patients must not have
scheduled cardiac surgery within 3 months after enroll-
ment. Patients gave written informed consent at enroll-
ment. The study was approved by the local ethical
committee and the Austrian competent authority.
Evia pacemakers
The Evia pacemakers (single chamber [SR/-T] and dual
chamber [DR/-T]) are suited for all standard indications
of bradycardia therapy. The contact surfaces of the pace-
makers are titanium and epoxy resin. All pacemakers are
rate-adaptive and multi-programmable. The Evia pace-
maker offers atrial and ventricular capture control, ven-
tricular pace suppression (VpS) algorithm and IEGMtransmission via Home Monitoring (SR-T and DR-T only).
For this study the Evia pacemakers (SR-T and DR-T) were
used together with the Safio S pacemaker leads. These
pacemaker systems are conditionally MRI CE-approved.
Safety and efficacy of the Evia pacemakers have been
approved previously [11].
Safio s leads
The Safio S is an active-fixation, transvenous, bipolar,
endocardial lead designed for permanent atrial or ven-
tricular stimulation and sensing. The lead is insulated
with silicone, and has an IS-1 connector. The Safio S is
flexible between the tip and ring electrodes and has an
isodiametric design with a diameter of 6.6 Fr. The Safio
S lead is a follow-up product of the Setrox S lead. The
safety and efficacy of the Setrox lead was demonstrated
earlier [12].
Home monitoring
The Evia DR-T and SR-T pacemakers have the ability
to transmit and receive data over a distance of several
meters using bi-directional long-range telemetry, i.e.
without the need of a programming wand. The data
is transmitted to a patient device (Cardio Messenger).
Via mobile phone technique, the Cardio Messenger
forwards the data to the Home Monitoring Service
Center. Safety and efficacy of remote monitoring by
Home Montoring in pacemaker patients have been
demonstrated recently [13].
Within this study, the pacemaker based programmable
Home Monitoring parameters were set as follows: auto-
matic transmission time 2:00 am; periodical EGM trans-
mission every 30 days; transmission in case of high atrial
frequency and sustained atrial episode (Evia DR-T only);
transmission in case of high ventricular frequency; kind
of report: trend report.
MR scans
MR scans were conducted under consideration of previ-
ously published recommendations for MR in pacemaker
patients [2,4-7]. After given written informed consent
patients underwent a non-diagnostic MRI of the brain
and the lower lumbar spine at 1.5 Tesla.
Before MR patients were asked for potential contra-
indications for MR scan. Tables 1 and 2 show in detail the
MR scan protocols for the brain and for the lower lumbar
spine, respectively. The brain scan consisted of 9 sequences
with a total expected scan time of 14.5 minutes, and a
dedicated receiving brain coil was used. Since MR scans
were of a non diagnostic intention the last 2 sequences of
the brain examination (CE-MRA and Perfusion) were per-
formed without the administration of contrast agent. The
lower lumbar spine scan consisted of 6 sequences and was
expected to last 14.8 minutes. For the lower lumbar spine
Table 1 MRI sequences for brain scan
Sequences for Philips MRI Scanner












































survey RefScan T1W_SE T2W_TSE T2W_FLAIR DWI_E S3DI_MC_HR 3D_DYN_AVM sPRESTO
plane ax/cor/sag - ax ax ax ax ax sag ax
Scan time 0:17 0:51 02:39 02:13 03:18 00:36 02:52 00:51 0:50
stacks 3 2 1 1 1 1 1 1 1
slices 3 each 82 18 18 16 18 100 10 30
Scan technique T1-TFE SENSE SE SE IR SE FFE FFE FFE
Fast imaging
mode
TFE - MS TSE TSE EPI none none EPI
(Turbo/EPI)
Factor
42 - 1 19 23 89 - - 19
TE [ms] 5.2 0.95 15 100 120 104 6.9 1.27 shortest
TR [ms] 15 8 483 3607 6000 3034 24 5 22
TI [ms] - - - - 2000 - - - -
Flip angle [deg] 20 7 140 90 100 90 20 35 7
FOV [mm] 250 - 230 230 230 230 200 260 220
Scan [%] 74 82 79 74 68 79.6 57.4 100 55.8
Scan matrix 256 x 126 64 x 52 256 x 163 384 x 228 208 x 115 112 x 89 332 x 190 160 x 144 64 x 29
Slice thickness
[mm]acq/rec
10 - 5 5 6 5 1 / 0.5 16 / 8 3.5
Slice gap 0 1 1 2 1 - - -
NSA / NEX 1 3 2 3 2 1 1 1 1
Bandwidth
[Hz/pixel]
186.9 2540.7 109.3 224.0 152.9 1834 108.8 541.1 60.3
Wollmann et al. Journal of Cardiovascular Magnetic Resonance 2012, 14:67 Page 3 of 11
http://www.jcmr-online.com/content/14/1/67scans an incorporated lumbar spine coil was used. Before
performing the MR scans pacemakers were programmed
to the MR mode (ProMRI feature). Within this feature the
pacing mode was programmed according to the require-
ments of the patients to an asynchronous single chamber
(A00 or V00), dual chamber mode (D00) or was deacti-
vated (OFF). In case of programming an asynchronous
pacing mode, the lower rate was automatically set to
80 bpm, and the output to 4.8 Volts/1.0 ms. Different
pacemaker functions (e.g. capture control, memory func-
tions) were deactivated during active ProMRI mode auto-
matically. Upon programming the pacemaker in the
ProMRI mode the Home Monitoring transmission system
is automatically rendered inactive (i.e. OFF). Thus no risks
of interferences between data transmission and MR sys-
tem are to be expected.
There were certain restrictions to be considered for
MR scans: since Evia pacemakers have an exclusion zonefor the isocenter landmark (exclusion zone: below the
level of the eyes and above the level of the major tro-
chanters), the iso-center landmark had to be placed at
the level of the eyes for brain scan, and at the level of
the major trochanters for lumbar spine scan, respect-
ively. The patient had to be in a supine position. No
additional local sending inductors were allowed. The
gradient slew rate had to be ≤ 200 T/m/s. The whole
body specific absorption rate (SAR) had to be ≤ 2 W/kg,
whereas the head SAR had to be ≤ 3.2 W/kg, respect-
ively. The scanning time per MR session should not ex-
ceed 30 minutes.
During MR patients were monitored using a MR com-
patible telemetry based ECG and pulse oximetry (In vivo
Corporation Orlando, FL, USA). ECG and pulse
oximetry curves were continuously observed by the first
author and recorded on digital video tape for the pur-
pose of (primarily not intended) retrospective evaluation.
Table 2 MRI sequences for lumbar spine scan
Sequences for Philips MRI Scanner
Body Region: Lumbar Spine, Patient Position: Supine, Patient Entry: Head First, Landmark on Trochanter















Spine-lumbar Spine-lumbar Spine-lumbar Spine-lumbar Spine-lumbar Spine-lumbar
Sequence Name
Philips
survey T1W_TSE_SAG T2W_TSE_SAG T1W_TSE(2)_TRA T2W_TSE(2)_TRA STIR_longTE_SAG
plane ax/cor/sag sag sag ax ax sag
Scan time [min] 0:28 02:32 02:12 02:59 03:23 03:13
stacks 3 1 1 3 3 1
slices 3 each 9 9 5 5 9
Scan technique FFE SE SE SE SE IR
Fast imaging
mode
none TSE TSE TSE TSE TSE
(EPI/Turbo)
Factor
5 21 4 18 17
TE [ms] 3.9 8 120 8 120 80
TR [ms] 23 380 2825 325 3500 3400
TI [ms] - - - - - 165
Flip angle [deg] 45 90 90 90 90 -
FOV [mm] 400 160 160 200 200 160
Scan [%] 74.6 72.3 72,7 77.7 76 70.5
Scan matrix 268 x 200 176 x 240 176 x 241 224 x 174 224 x 171 176 x 238
Slice thickness 10 4 4 4 4 4
Slice gap user defined default default default default user defined
NSA / NEX 2 4 4 6 6 4
Bandwidth [Hz/
pixel]
285.9 196.6 324,7 198.4 139.9 297.1
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alarm in case of emergency. Emergency equipment was
available onsite. After MR patients were asked for un-
usual perceptions (e.g. local heating, pacemaker vibra-
tion etc.) during MR scans.
Primary study endpoints
Primary endpoint #1: MRI and pacing system related
serious adverse device effect (SADE) free-rate
While all adverse events had to be recorded throughout
the entire study, only the number of possibly pacing sys-
tem and MRI related SADEs were the basis for endpoint
calculation of the SADE rate. A SADE was pacing sys-
tem related if it resulted from the presence or perform-
ance of the pacing system. A SADE was MR related if it
occurred due to the interaction of the pacing system
with the MR procedure. This was the case if the patient
was within the 5 Gauss line of the MR system or if the
SADE occurred in the month following the MRprocedure. SADE’s due to programming the pacemaker
to MR mode were also classified as MR procedure
related. Pocket and lead infections were described but
not taken into account for the primary endpoint.
The parameter of interest pSADE was the SADE free rate
per patient, which was calculated by 100% - (number of
SADE divided by the number of patients)* 100%. It was
expected, that this SADE free rate will be greater than 90%.
Primary endpoint #2: Pacing threshold rise (atrial and
ventricular)
The percentage of pacing leads with a pacing threshold
rise between pre-MR follow-up (baseline FU) and 1-
month follow-up (2nd FU) was investigated. The thresh-
old behavior of the lead was defined as a success if the
increase was not larger than or equal to 1.0 Volts. Only
measurements of the same polarity (either uni- or bipo-
lar) were taken into account. The proportion (pPT) of
pacing threshold successes was calculated by dividing
Table 3 Patient demographics
N %
Total patients 30 100
Female 12 40
Age (years) 73 ± 12
Height (cm) 169 ± 0.1
Weight (kg) 80 ± 16
Body mass index 28 ± 5
Pacemaker indication
Higher degree AV block 10 33
Sick sinus syndrome 6 20
Brady-/Tachy-Syndrome 7 23
AF with significant bradycardia 7 23
AP (DC-PM only;%; [median]) 34 ± 33 [27]
VP (%; [median]) 63 ± 31 [63]
AF-Burden (DC-PM only;%; [median]) 11 ± 28 [0]






Evia SR-T 15 50
Evia DR-T 15 50
Implanted leads
RA: Safio S 53 cm 15 50




Implantation site left pectorally 30 100
PM pocket subcutaneously 24 80
Time from implantation (months) 2.6 ± 1.7
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defined above by the total number of all leads.
Secondary study end-points
P-wave sensing attenuation
The P-wave sensing attenuation rate (pMRI Psensing) was
the percentage of patients who experienced a P-wave
sensing amplitude attenuation. P-wave amplitude attenu-
ation was defined as either a P-wave amplitude decrease
(between pre-MRI follow-up and 1-month follow-up)
exceeding 50% or a P-wave amplitude at 1-month fol-
low-up smaller than 1.5 mV. In case that a patient ful-
filled both conditions he/she was counted only once.
The proportion (pMRI Psensing) was calculated by dividing
the number of patients with P-wave sensing attenuation
by the total number of patients. Only measurements of
the same polarity (either uni- or bipolar) were taken into
account. Patients with a P-wave sensing amplitude smal-
ler or equal to 1.5 mV at pre-MRI were excluded from
the analysis of this endpoint.
For comparison: In the Setrox S Master Study the per-
centage of patients with a P-wave sensing amplitude lower
than 1.5 mV at the 3-month follow-up was 4/109=3.7%. In
the same study, the percentage of patients with an ampli-
tude decrease exceeding 50% between 1-month and 3-
month follow-up was 1/97=1.0%. This one patient had also
a sensing amplitude below 1.5 mV and therefore was not
counted double. Hence a percentage (pSetrox Psensing) of 3.7%
resulted. For the purpose of this study the difference be-
tween the percentages were calculated via: ΔP-wave sensing =
pMRI Psensing – pSetrox Psensing and was expected to be zero
or less.
R-wave sensing attenuation
The R-wave sensing attenuation rate (pMRI Rsensing) was
the percentage of patients who experienced a R-wave
amplitude attenuation. R-wave amplitude attenuation
was defined as either a R-wave amplitude decrease
(between pre-MRI follow-up and 1-month follow-up)
exceeding 50% or a R-wave amplitude at 1-month fol-
low-up smaller than 5.0 mV. In case that a patient ful-
filled both conditions he/she was counted only once.
The proportion (pMRI Rsensing) was calculated by dividing
the number of patients with R-wave sensing attenuation
by the total number of patients. Only measurements of
the same polarity (either uni- or bipolar) were taken into
account. Patients with a R-wave sensing amplitude smal-
ler or equal to 5.0 mV at pre-MRI were excluded from
the analysis of this endpoint.
For comparison: In the Setrox S Master Study the per-
centage of patients with a R-wave sensing amplitude
lower than 5.0 mV at the 3-month follow-up was 3/
61 = 4.9% [8]. In the same study, the percentage of
patients with a sensing decrease exceeding 50% between1-month and 3-month follow-up was 0/51 = 0.0%. There-
fore the percentage (pSetrox Rsensing) resulted to 4.9% [8].
For the purpose of this study the difference between the
percentages was calculated via: ΔR-wave sensing=pMRI Rsensing –
pSetrox Rsensing and was expected to be zero or less.Follow-up
Pacemakers were interrogated immediately before (base-
line FU) and immediately after (1st FU) MR to assess po-
tential changes of lead parameters (right atrial (RA)/
right ventricular (RV) sensing [mV], pacing threshold
[V/0.4 ms], pacing impedance [Ohm]) as well as of bat-
tery status (100% or less). Patients were followed for
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(2nd FU) and 3 months (3rd FU) after MR. Additionally,
patients were remotely monitored using Home Monitor-
ing based on routinely scheduled 30-day or event trig-
gered transmissions.
Statistical analyses
Continuous variables are expressed as mean± SD. The
effects of MR on sensing, pacing thresholds, and lead im-
pedance were analysed by one-way ANOVA, for paired
data followed by post-hoc analysis (Student’s paired t-test).
Categorical variables were compared using the chi-square
test and the Fisher’s exact test, where appropriate. Box
plots display the following descriptive measurements:
sample minimum: lower end of the whisker; Q1 (lower
quartile): bottom of the box; Q2 (median): line inside the
box; Q3 (upper quartile): top of the box; sample max-
imum: upper end of the whisker; mean: diamond inside
the box; outliers: circles). A p-value < 0.05 was considered
significant.
Results
Thirty-one patients were enrolled. One male patient with
an Evia DR-T had to be excluded because of an enroll-
ment violation. The patient underwent scheduled surgery
for single coronary bypass of the circumflex artery origin-
ating from the right coronary artery 4 weeks after the MR.
The surgery was indicated before enrollment. Therefore,Table 4 Measurements during MR scans
Scan sequence SAR (W/k
Hea
3 plane localizer Head CNS-Brain 0.3 ± 0
Reference Scan Ref Scan 0.3 ± 0
AX SE T1 Head CNS-Brain 2.0 ± 0
AX FSE T2 Head CNS-Brain 1.6 ± 0
T2 Flair Head CNS-Brain 0.5 ± 0
Diffusion Head CNS-Function 0.2 ± 0
3D TOF MT Head CNS-Angio 1.8 ± 0
CE-MRA Head CNS-CE-Angio 1.9 ± 0.2
Perfusion Head CNS-Angio 0.2 ± 0.9
Total scan time (min)
Lumbar
Localizer center at L1 Survey 0.3 ± 0
Sagital T1 Isocenter at L1 T1W_TSE_SAG 2.0 ± 0
Sagital T2 Isocenter at L1 T2W_TSE_SAG 2.0 ± 0
Axial T1 Isocenter at L1 T1W_TSE (2)_TRA 2.0 ± 0
Axial T2 Isocenter at L1 T2W_TSE (2)_TRA 1.6 ± 0
Sagital T1 Isocenter S1 STIR_long TE_SAG 1.9 ± 0
Total scan time (min)30 patients are included in the following data analyses.
Table 3 shows the characteristics of the patient cohort.
The leading pacemaker indication was intermittent or per-
manent higher degree AV block (n= 10 [33%]). Half of the
patients had been implanted with dual chamber pace-
makers. In a minority of patients (n= 6 [20%]) permanent
pacemakers were placed in an intra- or sub pectoral
pocket, mainly due to thin subcutaneous fatty tissue. The
time from pacemaker implantation to enrollment/MR
scan was 2.6 ± 1.7 months (median 1.7 months).
MR scans
Before MR all pacemakers were followed and were pro-
grammed according to the protocol. In all patients who
were not pacemaker dependent (n = 21 [70%]) the pacing
function was deactivated.
Tables 1 and 2 show the scan protocols for head and
lower lumbar spine scan, respectively. Table 4 shows the
mean values of SAR, scan duration and gradient strength
for the different scan sequences. The total scan time of
the brain scan was 14.0 minutes, of the lumbar spine
scan 15.2 minutes, respectively.
In one patient, metallic artifacts surprisingly were
recognized during the 1st (survey) sequence of the head
scan. MR was immediately stopped. After performing x-
ray demonstrating the metallic artifact (very small splin-
ters) to be outside the osseous head and the decision
that MR wouldn’t cause any harm to the patient, theg) Scan duration (sec.) Gradient strength (% PNS)
d
17.6 ± 3.1 16.0 ± 0
78.3 ± 13.9 19.5 ± 1.4
101.0 ± 0 12.1 ± 1.6
133.0 ± 0 36.8 ± 0.6
198.0 ± 0 30.5 ± 0.6
36.0 ± 0 52.7 ± 1.2
169.0 ± 0 35.9 ± 4.7
56.0 ± 0 14.0 ± 0
51.0 ± 0 51.2 ± 9.7
14.0
spine
53.0 ± 0 17.0 ± 0
158.0 ± 0 38.7 ± 1.3
132.0 ± 0 40.0 ± 0
179.0 ± 0 40.0 ± 0
203.0 ± 0 39.6 ± 2.0
193.0 ± 0 41.0 ± 0
15.2
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col was completed. The metallic splinters were unknown
even to the patient and might be the result from work-
ing with an angle grinder.
None of the patients reported about uncomfortable
feelings or other disorders during MR possibly related to
the pacemaker.
MR scans were performed in a non-diagnostic manner,
but were analyzable concerning rough conspicuous-
nesses. Analyses of MR scans revealed no important in-
cidental findings.
After completion of all MR sequences pacemakers
were interrogated again and re-programmed. Total time
from activation to deactivation of the ProMRI feature
was 73 ± 17 minutes (median 74).
Adverse events
MRI related adverse events
No MRI related early or late adverse events occurred. There-
fore, the 1st primary endpoint was met (pSADE=100%).
Other adverse events
There were 4 AEs. All AEs were not MR related. One fe-
male patient (age 56 years, bradycardia/tachycardia syn-
drome, normal left ventricular function (LVF) prior to
PM implantation, VVI-PM [apical lead position]) suf-
fered twice from cardiac decomposition (1st episode
43 days after MR, 2nd episode 66 days after MR) pre-
sumably due to the effects of frequent pacing from the
right ventricular apex (ventricular pacing: 61% at base-
line FU, 70% at 2nd FU) as well as of intermittent rapidly
conducted atrial fibrillation. Echocardiography revealed
a significantly reduced LVF at the time of first cardiac
decomposition. Another female patient (age 83 years,
higher degree AV block, DR-PM) was admitted 11 days
after MR to our emergency department due to suspected
deep vein thrombosis of the left lower leg (which was
excluded). One male patient (age 85 years, coronary
artery disease, status post CABG, persistent atrialFigure 1 Patient #31. Episode print-out of spontaneously occurring VT atfibrillation, VVI-PM) died suddenly 17 days after MR.
The patient was admitted to our emergency department
10 days after the MR scan because of newly recognized
icterus. During the in-hospital stay pancreatic carcinoma
with disseminations was diagnosed. On 14th of August,
2 hours after discussion about prognosis of the malig-
nant disease and potential further diagnostic and thera-
peutic options the patient died suddenly. Autopsy
revealed a large myocardial infarction as underlying
cause of death. Post mortem PM interrogation showed
fast VT at the time of death (Figure 1).
Lead measurements
Since one patient died before passing the 1-month FU,
calculation of the study endpoints is based on the data
of 29 patients. The 1-month follow-up took place after a
mean of 1.1 months after the MR procedure, the 3-
month follow-up after 3.0 months, respectively.
All lead measurements were done in a bipolar config-
uration. Except for RV pacing impedance assessed im-
mediately after the MR paired Student’s t-test revealed
no significant differences of lead dependent parameters
as well as of battery status between the pre-MRI FU and
all other FUs. Table 5 gives an overview of all measure-
ments from all available FUs.
Atrial pacing threshold
Atrial pacing thresholds showed a slight increase in the
course after the MRI scans (Figure 2a). The measured
values were not significantly different between the
follow-ups (Table 5). One patient had an increase of the
atrial pacing threshold by 75% (from 0.4 V/0.4 ms to
0.7 V/0.4 ms) from the 1st FU to the 2nd FU. There was
no further change observed until the 1-month FU.
Ventricular pacing threshold
Ventricular pacing thresholds showed a slight increase be-
tween the 1-month FU and the 3-month FU (Figure 2b),the time of myocardial infarction/death.
Table 5 Lead Measurements and Battery status
Follow-up
Parameter 1st FU (n= 30) 2nd FU (n = 30) 3rd FU (n = 29) 4th FU (n = 29) p = *
Time from MRI (months) - - 1.1 ± 0.3 3.0 ± 0.3
RA sensing (mV) 3.2 ± 2.1 3.2 ± 2.3 3.2 ± 2.1 3.1 ± 2.0 n.s.
RA pacing threshold (V@0,4 ms) 0.68 ± 0.18 0.67 ± 0.16 0.71 ± 0.24 0.73 ± 0.15 n.s.
RA pacing impedance (Ohms) 507 ± 55 500 ± 46 520 ± 50 495 ± 59 n.s.
RV sensing (mV) 15.0 ± 6.0 15.0 ± 6.0 14.9 ± 6.5 14.7 ± 6.3 n.s.
RV pacing threshold (V@0,4 ms) 0.78 ± 0.22 0.79 ± 0.20 0.78 ± 0.22 0.82 ± 0.24 n.s.
RV pacing impedance (Ohms) 608 ± 54 599± 52+ 607 ± 47 597 ± 57 n.s.
Battery status (%) 100 ± 0 100± 0 100± 0 99.7 ± 1.3 n.s.
Value changes (% [median]; compared with pre MRI FU)
RA sensing −2± 20 [0] +6 ± 43 [0] +15± 57 [8]
RA PTH +2± 23 [0] +2 ± 30 [0] +9 ± 7 [0]
RA Pimp −1 ± 4 [0] +3 ± 6 [4] −2 ± 11 [0]
RV sensing −1 ± 6 [−1] −2 ± 12 [−2] −4 ± 14 [−1]
RV PTH +2± 8 [0] 0 ±12 [0] 7 ± 24 [0]
RV PImp −2 ± 2 [−2] 0 ± 6 [0] −2± 7 [0]
Battery status 0 ± 0 [0] 0 ± 0 [0] 0 ± 1 [0]
Grey columns: relevant FUs for endpoint calculation.
*Oneway ANOVA.
+p < 0.05 when comparing with pre MRI values (paired t-test).
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ent (Table 5).
The female patient which decompensated twice
showed an increase of the ventricular PTH from 0.8 V/
0.4 ms at the 1-month FU to 1.5 V/0.4 ms at the 3-
month FU (+88%) most likely due to new rhythm con-
trol therapy with amiodarone.
All other atrial and ventricular pacing threshold
changes observed were less than 50%. None of the
patients had an increase of the atrial or ventricular PTH
by 1 Volt or more between the baseline FU and the 1-
month FU. Therefore, the second primary endpoint was
met (pPT = 1).
Atrial sensing
Values for atrial sensing were stable throughout the
study period (Table 5, Figure 2c). Three patients had an
atrial sensing of ≤ 1.5 mV at the pre-MRI FU and –
therefore – were excluded from calculation of the first
secondary endpoint. Since no one of the remaining
patients (n = 12) had an atrial sensing of < 1.5 mV or had
a sensing attenuation by ≥50%, also the first secondary
endpoint was met (pMRI Psensing = 0.0%). ΔP-wave sensing
was calculated to be −3.7%.
Ventricular sensing
Values for ventricular sensing were stable throughout
the study period (Table 5, Figure 2d). Two patients hadno intrinsic R wave (one at the pre-MRI FU, one at the
1-month FU), one patient died before the 1-month-FU.
These 3 Patients were excluded from calculation of the
second secondary endpoint. Since no one of the
remaining patients (n = 27) had a ventricular sensing
of < 5.0 mV nor had a sensing attenuation by ≥50%, also
the 2nd secondary endpoint was met (pMRI Rsensing =
0.0%). ΔP-wave sensing was calculated to be −6.9%.Home monitoring
Within the observational period more than 1800 data
sets were transmitted, composed of - amongst other
parameters – RA/RV Impedance, RA/RV Threshold,
RA/RV Sample Amplitude, RA/RV Sample Amplitude
Mean, Heart Rate (24 h) and Battery Status. Neither
hardware related annotations (e.g. pacing impedance
alert, battery depletion) were transmitted nor device
related (hardware/software) irregularities were found in
the status information based on routinely scheduled 30-
day or event triggered transmissions.Pacemaker associated MR imaging artifacts
In all patients the presence of the pacemaker caused an
inhomogeneity of the static magnetic field in the mid
face and the frontal lobe areas resulting in a MR imaging
artifact on diffusion weighted sequences of the brain
(Figure 3).
Figure 2 The diagrams show the changes of RA-PTH (a), RV-PTH (b), P wave sensing amplitude (c) and R-wave sensing amplitude (d)
at the different FUs.
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This study is the first to report about functionality of the
MR conditional Evia pacemaker in a MR environment,
and the second study that reports about MR eligible
pacemaker systems undergoing MR [8].
The MR conditional Evia pacemakers with Safio S
leads demonstrated unobtrusive function under MR con-
ditions. The use of the Evia pacemakers with Safio S
leads in MR environment was feasible.
Since there were no MR related SADEs nor were signifi-
cant pacing threshold increases or sensing attenuations as
defined by the protocol all primary and secondary study
endpoints were met. Lead measurements were not affected
by MR immediately nor showed significant changes within
the observational period of 3 months.
The continuous observation of the ECG and pulseoxy
monitor showed no inhibition of pacemaker stimulation,
sustained or non-sustained atrial and/or ventriculararrhythmias, asystole, or other unexpected changes of
heart rate occurred in the context of MR scans. Also no
conspicuousnesses concerning pacemaker statistics and
the functions or the electrical integrity of the devices oc-
curred during or after MR. No patient reported unusual
feelings/sensations that potentially were related to the
pacemaker while being in the MR environment. Observed
differences in lead measurements between the different
follow-ups were in clinically accepted ranges.
The observed pacemaker associated MR imaging artifact
of the brain on diffusion weighted images (Figure 3) may
have no relevant clinical importance, since the image qual-
ity of the remaining sequences such as FLAIR and T2
weighted spin-echo images is not affected (Figure 3).
As recommended patient surveillance during the MRI
scans was realized by using a combination of ECG and
pulse oximetry [2-7]. Verbal contact with the patient
was nearly impossible especially during the brain scan.
Figure 3 Left: Diffusion weighted gradient echo image. Notice pacemaker associated distortion of the image in the frontal region of the
brain. Right: T2 weighted spin echo image (identical slice location) showing normal anatomy not affected by the presence of a pacemaker.
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during MR scans and only useable in-between the MR
sequences. Our experience is that only pulse oximetry in
conjunction with a patient activated alert system seems
to be reliable for patient surveillance during total scan
time, whereas ECG with appropriate quality is reliable
only occasionally during the scans.
Another finding of the study is that patients were pro-
grammed to the ProMRI mode for a mean of 73± 17 min-
utes. This fact has impact on patient surveillance not only
during MR scan, but also before and thereafter. This long
period observed in our study was a result from cumulative
30 min MR scans, changing the body position in relation
to the MR bore between the two different scans, taking off
clothes before and on thereafter, and placement of the
technical equipment for the purpose of patient surveil-
lance. Additional time was needed for awaiting availability
of the MR scanner since study scans were performed
within daily routine of the private radiology institute. Al-
though the pacing function was set in all non-pacemaker
dependent patients (n= 21 [70%]) to OFF when we pro-
grammed the pacemakers into the ProMRI mode, the long
period our patients remained in the ProMRI mode had no
impact on patient safety within our study since pacemaker
programming was done in or near the control room of the
MR scanner, and patients never were on their own. But
what to do in the case pacemaker programming is located
far away from the MR scanner (e.g. out-patient pacemaker
office and radiology department located in different facil-
ities). In this case, programming the pacemaker off may
provoke complications like syncope on the way to or back
from the scanner. This scenario may be unlikely in this
low-risk patient group, but would have legal implications
if it happens. There are several ways to overcome this
problem. The personnel intensive way is to guide thepatient e.g. from the pacemaker out-patient clinic to the
MR scanner and later back again. Another way is to re-
motely activate/deactivate the specific MR mode just
when the patient enters/leaves the room where the MR
scanner is located. Of course, one could abstain from pro-
gramming a different than an asynchronous pacing mode.
Indeed asynchronous pacing was judged to be safe, but
only for a short time as it usually is used during pace-
maker follow-up [14]. Seen from this point of view there
was (and would have been) long term asynchronous
pacing in our cases. This fact may be another source of
hidden danger when performing MR even in patients with
MR conditional pacemakers and all those who are
involved should be aware of this [15].
Limitations
The major limitation of our study is the limited number
of patients and the non-randomized and – therefore –
statistically not powered study design. However, the
intention of the study was to collect experience in order
to prepare the ProMRI AFFIRM master study of the
MRI compatibility of the Evia/Entovis pacemaker in
combination with Safio S leads.
Conclusion
The new MR conditional Evia pacemaker system demon-
strated unobtrusive function under MR conditions.
Observed differences in lead measurements between the
different follow-ups were in clinically accepted ranges. No
MR related adverse events occurred. Pacemaker related
MR imaging artifacts occurred on diffusion weighted
sequences of the brain, but may have no clinical relevance.
Our study demonstrated feasibility and safety of Evia
single chamber and dual chamber pacemakers with Safio
S leads in a MRI environment under well defined
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http://www.jcmr-online.com/content/14/1/67conditions. The long duration patients remained in the
specific MR pacemaker programming mode (ProMRI)
may have impact on patient safety and, therefore – will
influence working algorithms for safe performance of
MR in patients even with MR conditional pacemaker
systems.
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